This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer. my.naviGATE is a m…

SarcomaOsteosarcomaEwing Sarcoma+6 more

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07516353

Phase 2

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…

Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more

~Estimated

~$10 – $7,500

Seda S. ToluNCT07283822

← PreviousPage 2 of 2Next →